CDNA · CareDx, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 7M | the fourth quarter | — |
| Average revenue per test | $1,480 | the fourth quarter | — |
| Average share repurchase price | $15.79 | the fourth quarter | — |
| Cash flow from operations | 21.4M | the fourth quarter | — |
| Share repurchases | 12M | the fourth quarter | — |
| Testing services volume | 53,000 | the fourth quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CDNA
this stock
CareDx, Inc.
|
$1.85B | +89.8% | +18.9% | — | 12.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$214.21B | -0.4% | +0.4% | 31.7 | 1.4% |
|
DHR
Danaher Corp /De/
|
$139.93B | -12.7% | +8.5% | 35.3 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.93B | -15.8% | +10.4% | 41.9 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$40.55B | +7.8% | +41.6% | 30.2 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CDNA | -6.8% | +24.1% | +75.1% | +25.4% | +89.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -5.8% | +24.1% | +67.6% | +26.2% | +81.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.